Norvartis submits Gleevec sNDA in USA

18 October 2001

Novartis has submitted a supplemental New Drug Application to the USFood and Drug Administration for its cancer treatment Gleevec (imatinib mesylate), for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumors for which, until now, surgery has been the only treatment option.

Gleevec is currently approved for marketing in more than 30 countries for the treatment of chronic myeloid leukemia in blast crisis, accelerated phase or in chronic phase after failure of interferon-alfa therapy (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight